Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Can you import TB-500 into the US?

Personal use is not a general import right for TB-500. FDA discretion is narrow, and federal law allows refusal of noncompliant articles.

Why we wrote this. US readers need FDA discretion, customs review and the statute separated from seller claims about personal use.

In this article (10 sections)
  1. TL;DR
  2. What the approval check established
  3. FDA's personal-import rule
  4. The statutory border layer
  5. What officials may flag
  6. Visitors follow a separate policy
  7. Grey-market availability is not permission
  8. If a parcel is detained
  9. What we do not yet know
  10. Medical and regulatory disclaimers

For an ordinary US consumer order, personal use does not create a right to import TB-500. FDA says that, in most circumstances, individuals may not import drugs bought abroad when the products have not been approved for use and sale in the United States[1]. A current search of the official Orange Book files found no entry for TB-500 or the searched thymosin beta-4 identity variants[2].

FDA can exercise enforcement discretion in narrow personal-import situations, but its listed factors are not a safe harbour. Calling a vial research material, limiting the quantity or finding a seller willing to ship does not establish admissibility. No official source we reviewed sets a TB-500-specific quantity threshold or guarantees that a parcel will be released.

TL;DR

The supported answer is no for a routine personal-use purchase. FDA describes importation of unapproved foreign drugs as illegal in most circumstances. Its discretionary factors include the condition being treated, domestic availability, risk, promotion to US residents, written personal-use affirmation and treatment documentation. The often-quoted three-month amount is only one factor. At the border, FDA and CBP review the actual article and declaration; federal law permits refusal when an article appears adulterated, misbranded or in violation of the drug-approval provision.

What the approval check established

FDA's Orange Book is an official inventory of approved drug products. On 15 November 2026, we downloaded the compressed data file and searched products.txt, patent.txt and exclusivity.txt without case sensitivity. The terms were TB-500, TB 500, TB500, thymosin beta-4, thymosin beta 4 and thymosin beta4. Every search returned zero matches[2].

That is a bounded database result. It supports saying that no matching approved finished product was identified under those names in the files checked. It does not authenticate any online vial, determine what a shipment contains or prove that no confidential development work exists. Approval attaches to a defined application and finished product, not automatically to a peptide nickname or a related protein name.

Identity also needs care. TB-500 is commonly used as a commercial name for a short peptide associated with thymosin beta-4, while scientific literature may discuss the full-length protein. A label that says thymosin beta-4 is not therefore enough to show that a vial is TB-500, and neither term supplies an FDA application number. Border review concerns the article actually offered for entry and the claims, labeling and documentation that accompany it.

FDA's personal-import rule

FDA defines personal importation as bringing or sending a product that is not for further sale or distribution in US commerce. For US citizens, the agency states that it is illegal in most circumstances to import drugs for personal use when foreign products have not been approved by FDA for US use and sale. Approval in another country does not by itself change that result[1].

The same page describes situations in which FDA personnel may consider a more permissive decision. For a serious condition, effective treatment may need to be unavailable domestically through commercial or clinical means. The product should not present an unreasonable risk, there should be no known commercialization or promotion to US residents, and the consumer should affirm in writing that the product is for personal use[1].

Quantity and documentation are additional factors. FDA says the amount is generally no more than a three-month supply, accompanied by either the name and address of the US-licensed doctor responsible for treatment or evidence that the product continues treatment begun abroad[1]. These conditions work together. A three-month amount is not an exemption, entitlement or molecule-specific threshold.

A retail TB-500 listing promoted to US buyers can sit uneasily with the no-commercialization factor. A seller invoice is not physician documentation. Nor does a research-use-only statement establish continuation of treatment abroad. FDA's policy asks about the real purpose and circumstances; wording added by a vendor cannot settle those questions.

The statutory border layer

The governing border authority is broader than the personal-import guidance. Section 801 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. section 381, provides for examination of imported articles. It says an article shall be refused admission when examination or other information makes it appear adulterated, misbranded or in violation of the new-drug approval provision in section 355, among other listed grounds[3].

FDA's import-basics page explains the agency split in operational terms. All products offered for US entry, including personal-use items, must be declared to Customs and Border Protection. CBP refers FDA-regulated products to FDA for review. FDA checks compliance with its requirements and may refuse noncompliant products; refused articles must generally be exported or destroyed within the stated period[4].

These sources do not create a TB-500 parcel-size rule. They also do not support a prediction that every parcel will be seized. The legal test is whether the article appears to fall within a refusal ground, while agency enforcement and examination depend on the facts available for that shipment. A delivery that passes through is not approval and does not bind the agencies on a later parcel.

What officials may flag

FDA's personal-import page lists refusal concerns that include an FDA import alert for previous violations, apparent commercial distribution, a product that appears to present a serious health risk, or an FDA-regulated article that appears to represent health fraud[1]. These are general official factors, not a secret TB-500 checklist.

Product description, quantity, manufacturer, claims and paperwork can help officials understand the article. A vague declaration such as peptide, supplement or laboratory material does not establish what the parcel contains. Misdescription is not a solution and can create a separate customs problem. We do not provide labeling tactics, routing advice or methods intended to avoid review.

Repeated shipments or quantities suggesting resale may support a commercial-distribution concern, but one small parcel is not automatically admissible. The absence of repeated orders does not turn an unapproved product into an approved one. Likewise, a certificate supplied by the seller cannot establish the chain of custody, sterility or identity of the unit at the border.

Visitors follow a separate policy

FDA gives separate guidance for foreign nationals visiting the United States. It says foreign nationals may bring or ship a 90-day supply of drug products and suggests documentation such as a visa or passport, a doctor letter and a prescription in English[1]. That visitor policy is not a 90-day purchasing rule for a US citizen or permanent resident.

A genuine visitor still needs documentation connecting the person, product and treatment. The page does not say that an unidentified research vial is accepted simply because its volume is small. US residents cannot convert themselves into visitors by using a foreign address or attaching travel documents to an ordinary retail order.

Grey-market availability is not permission

TB-500 can be advertised online, but availability does not establish approval, legal import status or product identity. Terms such as laboratory grade, pharmacy made and independently tested are commercial claims unless supported for the exact unit. None supplies the missing FDA application or guarantees admission at the border.

We do not name vendors, compare claimed seizure rates, repeat reshipment promises or describe concealment methods. Such details could facilitate an unapproved purchase while leaving the legal and quality questions unresolved. A refund policy is a contract term between seller and buyer, not evidence that FDA or CBP permits importation.

For identity and evidence context, see the TB-500 overview. For the wider federal framework, use the United States regulation hub. Neither page authenticates an online product or offers a route around border controls.

If a parcel is detained

Read the official notice rather than relying on the seller's interpretation. Identify the agency, article description, stated reason, response deadline and contact route. A real detention can involve facts not visible from a tracking page. Use the contact in the notice and seek qualified US legal advice when the consequences matter.

Do not assume that splitting an order, changing a description or trying another courier would make it lawful. The supported question is whether the exact article is approved or falls within a documented route. The approval search described above found no matching TB-500 product, and the official personal-import policy remains discretionary.

What we do not yet know

FDA and CBP do not publish a TB-500-specific interception rate, safe package size or port-by-port release probability. We found no official molecule-specific threshold. We therefore cannot estimate whether a particular parcel will be detained, and the absence of public statistics must not be presented as permission.

The official sources also cannot identify the contents of a seller's vial without examination of that unit. A product name, analytical report or successful prior delivery does not establish identity for the next shipment. These gaps are why the answer stays focused on approval records, the published discretionary policy and the statute rather than anecdotes.

The supported conclusion is narrow but clear: ordinary personal use does not make a purported TB-500 shipment lawful to import. FDA's three-month language is one factor, not a safe harbour, and federal law permits refusal when an article appears to violate the relevant drug requirements. Discuss health decisions with a qualified clinician and case-specific import questions with FDA or a US lawyer.

Medical and regulatory disclaimers

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Regulatory disclaimer: This page reflects our understanding of the regulatory status as of 15 November 2026. Regulations change. Verify with the official regulator before making any decision. PeptideMethods.com is not a law firm and does not provide legal advice.

Frequently asked

Can I import TB-500 into the US for personal use?

Not through an ordinary consumer order merely labelled personal use. FDA says unapproved foreign drug imports are illegal in most circumstances, while its more permissive policy is discretionary and conditional.

Does FDA allow a three-month supply of TB-500?

There is no blanket three-month allowance. Quantity is one factor alongside the condition, domestic availability, promotion, risk, written affirmation and clinician or treatment-continuation documentation.

Is there an FDA-approved TB-500 product?

No matching product was found in the current Orange Book files searched on 15 November 2026 for TB-500 and listed thymosin beta-4 variants. That is a bounded database finding.

What can cause a TB-500 parcel to be refused?

FDA lists import-alert history, apparent commercial distribution, serious health risk and apparent health fraud as concerns. The statute also permits refusal when an article appears adulterated, misbranded or in violation of the approval provision.

Does successful delivery make imported TB-500 legal?

No. Delivery is not FDA approval, product authentication or a precedent. It means only that a particular parcel reached its recipient.

Sources

  1. [1]US FDA: Personal Importation, content current 18 August 2025Tier 1 · primary↩
  2. [2]US FDA: Orange Book Data Files, searched 15 November 2026Tier 1 · primary↩
  3. [3]US Government Publishing Office: 21 U.S.C. section 381, 2024 editionTier 1 · primary↩
  4. [4]US FDA: Import Basics, content current 26 October 2026Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars